Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy

Inclusion Criteria: * Patients with Multiple Myeloma who Have Relapsed after 1-3 Prior Lines of Therapy * Women \> 50 years old * Κarnofsky performance status ≥ 60 (patients with lower performance status due to myeloma bone disease can also be included) * Measurable disease * Platelet count \>50x10(9)/L * Neutrophil count \>0.75x10(9)/L * Hemoglobin ≥7.0 g/dL (the use of recombinant human erythropoietin or red blood Hell transfusions to maintain hemoglobin levels above 7.0 g/dL is not an exclusion criterion) * Serum ALT and AST ≤ 3-fold of upper normal limit * Serum bilirubin ≤ 2-fold of upper normal limit * Serum Calcium ≤ 10.5 mg/dL * Expected survival ≥ 2 months * Signed informed consent Exclusion Criteria: * Presence of another cancer * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * Grade 2-4 peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3 * Pregnant women \> 50 years old or breast-feeding * Woman \> 50 years old capable of becoming pregnant \[anyone who has not undergone a hysterectomy, has not had both ovaries removed or has not been post-menopausal for more than 24 months in a row not using adequate contraception * Known or suspected hypersensitivity or intolerance to bortezomib, boron, mannitol, zoledronic acid, dexamethasone, or heparin (if an indwelling catheter is used) * Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose …